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Abstract: Matrix metalloproteinases (MMPs) are a class of zinc dependent endopeptidases which
play a crucial role in a multitude of severe diseases such as cancer and osteoarthritis. We employed
MMP-13 as the target enzyme for the structure-based design and synthesis of inhibitors able to
recognize the catalytic zinc ion in addition to an allosteric binding site in order to increase the affinity
of the ligand. Guided by molecular modeling, we optimized an initial allosteric inhibitor by addition
of linker fragments and weak zinc binders for recognition of the catalytic center. Furthermore we
improved the lipophilic ligand efficiency (LLE) of the initial inhibitor by adding appropriate zinc
binding fragments to lower the clogP values of the inhibitors, while maintaining their potency.
All synthesized inhibitors showed elevated affinity compared to the initial hit, also most of the novel
inhibitors displayed better LLE. Derivatives with carboxylic acids as the zinc binding fragments
turned out to be the most potent inhibitors (compound 3 (ZHAWOC5077): IC50 = 134 nM) whereas
acyl sulfonamides showed the best lipophilic ligand efficiencies (compound 18 (ZHAWOC5135):
LLE = 2.91).
Keywords: structure-based drug design; organic synthesis; matrix metalloproteinase inhibitors;
molecular recognition; weak zinc binders; lipophilic ligand efficiency
1. Introduction
As the most efficient contributor to degeneration of type II collagen within its superfamily of
zinc-dependant endopeptidases, matrix metalloproteinase-13 (MMP-13) is a highly validated target
for the treatment of diseases based on tissue degradation [1–5]. Unregulated MMP activity can lead
to a variety of diseases such as tumor growth and metastasis, periodontal disease and osteoarthritis
(OA) [6–12].
Initial success in developing inhibitors against MMP-13 was achieved over a decade ago by
modifying the natural substrate close to the scissile amide bond. By implementing structural elements
that cannot be hydrolyzed by the enzyme, peptidomimetics were obtained [13]. Potent inhibitors
resulted by adding strong zinc binding groups such as hydroxamic acid to interact with the catalytic
domain [14,15]. Those inhibitors lacked sufficient selectivity due to high structural similarity among
the various MMPs. Because of toxicity and severe side effects arising from scarce selectivity no
compound with strong zinc chelating groups such as hydroxamic acids has survived clinical trials so
far [16,17].
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Later generations of MMP-13 inhibitors did not bind to the catalytic zinc, but buried themselves
deeper in the S1’ pocket, occupying the specificity loop leading to inhibitors that combine high potency
with appealing selectivity profiles [18–25]. Adding weak zinc binding groups to those allosteric
inhibitors can lead to selective inhibitors with higher potency due to a dual binding mode (allosteric
pocket and catalytic center) [26].
A previous study conducted in our laboratory led to the identification of compound 1 (Figure 1)
with a lipophilic ligand efficiency (LLE = 1.07) which inhibits MMP-13 showing an IC50 value of 9.8 µM
without chelating the catalytic zinc ion [27].
Figure 1. Chemical structure of the previously identified inhibitor 1.
In this article we present a structure-based design approach to modify the allosteric MMP-13
inhibitor 1 to increase its potency by improving the molecular recognition between the enzyme and
its ligand. This could be achieved by the introduction of a weak zinc binding fragment in order to
interact with the catalytic center. Furthermore we enhanced the lipophilic ligand efficiency of the novel
compounds compared to the allosteric inhibitor.
2. Results
2.1. Molecular Modeling
In the first step of the design process we had a close look on the binding mode of 1 in the
allosteric binding pocket of MMP-13. We used the crystal structure PDB 2OW9 (Figure 2a) [24] to
dock the molecule into the cavity defining a pharmacophore query to maintain the three hydrogen
bonds to the backbone amino acids Thr224, Thr226 and Met232, formed by the oxygen atoms of the
phthalimide scaffold (Figure 2b). It turned out that a zinc binding group could be attached to the
molecule, favourably in meta position, to interact with the catalytic zinc ion (Figure 2c). As the distance
that has to be overcome added up to more than 5 Å (Figure 2d) we decided to implement a linker
consisting of four and more heavy atoms between the aromatic ring system and the chelating group.
Figure 2. Cont.
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Figure 2. (a) Co-crystal structure PDB 2OW9; (b) compound 1 docked to PDB 2OW9 with the
pharmacophore being fulfilled; (c) possibility of attaching a weak zinc binder in meta position;
(d) distance between ligand and zinc ion.
At the meta position of the aromatic ring an oxygen was added for synthetic reasons, followed
by aliphatic linker chains between 3–6 carbon atoms in length as well as a terminal hydroxy group.
The alcohol head group was implemented as a generic zinc chelator of small size to evaluate the
optimal linker length (Figure 3).
Figure 3. Docking poses of four molecules with different linker lengths and the zinc-chelating hydroxy
group (green: 3 CH2, yellow: 4 CH2, magenta: 5 CH2, cyan: 6 CH2).
We decided to focus on chain lengths of 4 and 5 carbon atoms (Figure 3, yellow and magenta) as
they showed lower root mean square deviation (RMSD) values (1.16 yellow and 1.35 magenta) than
the other two linkers (1.56 green and 2.57 cyan). This indicates better quality of the docking poses [28].
In addition, visual inspection of the docking poses indicated that chain lengths of 4 and 5 carbon atoms
seemed to cover the distance more efficiently than the other two linkers. Subsequently we examined
different head groups as potential zinc chelators. Therefore we modified structure 2 by implementing
a carboxylic acid (3), an acyl sulfonamide (4) and an amide (5) to obtain a set of ligands for which the
recognition of the catalytic zinc should increase their affinity to the protein and therefore enhance the
inhibitors potency (Figure 4) [29,30].
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Figure 4. Structural proposals for extended molecules to overcome the distance to the zinc ion,
including different weak zinc binders.
For the purpose of this evaluation we executed docking experiments applying the identical
pharmacophore as for the previously docked structure 1 (Figure 5a–d).
Figure 5. Highest ranked docking pose of (a) alcohol 2; (b) carboxylic acid 3; (c) acyl sulfonamide 4;
(d) amide 5, with the linker emphasized (green) and the head group showing the anticipated interaction
with the zinc.
All of the four examined weak zinc binding head groups showed the postulated molecular
recognition of the metal ion. The alcohol and the acid as well as the amide exhibit monodentate
binding, whereas the acyl sulfonamide acts as a bidentate chelator. According to our modeling
experiments, the carboxylic acid interacts as a monodentate ligand. This corresponds well with the
reported binding mode of carboxylic acids in the active site of MMP-13 (Figure 6, crystal structure PDB
1ZTQ [31]).
Int. J. Mol. Sci. 2016, 17, 314 5 of 15
Figure 6. Co-crystal structure of a carboxylic acid interacting with the zinc ion in the active site of
MMP-13 involving only one of the two oxygen atoms.
The designed compounds 2–5 displayed better scoring values (in the range of ´18) compared to
1 (´12.8). In consideration of the modeling results described above, we decided to synthesize a small
library of this type of molecules.
Figure 7. Synthesis of compounds 2–18. (a) Benzyl-n-bromoalkylether, Cs2CO3, DMF, RT, 18 h, 8a: 80%,
8b: 85%, 8c: 83%, 8d: 84%; (b) KOH 10% in H2O, methanol, RT, 30 min., 9a: 89%, 9b: 92%, 9c: 100%,
9d: 94%; (c) SOCl2, DIPEA, THF, RT, 2 h, 10a: 74%, 10b: 64%, 10c: 66%, 10d: 55%; (d) Pd/C 10%, ethanol,
RT, 2 h, 11: 57%, 12: 48%, 2: 83%, 13: 77%; (e) TEMPO, sodium phosphate 0.67 M in H2O pH 6.7,
NaClO2, NaOCl, ACN, 40 ˝C, 4 h, 14: 51%, 15: 84%, 3: 53%, 16: 87%; (f) EDC¨HCl, methanesulfonamide,
DMAP, DCM, 0 ˝C, 20 min., RT, 12 h, 17: 19%, 18: 26%, 4: 41%; (g) DIPEA, HATU, methylamine 2 M in
THF, THF, RT, 12 h, 5: 39%.
2.2. Chemistry
Driven by the positive results of our computational design approach towards molecular
recognition of the catalytic zinc ion, we synthesized compounds 2–5 according to the synthetic route
summarized in Figure 7. The benzylated aminophthalimide derivative 6 was prepared according to
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a previously described procedure [27]. The acid 9 was obtained by saponification of 8 which was
prepared by the nucleophilic substitution of 7 on benzyl-n-bromoalkylether. An amide coupling
between the alkylated aminophthalimide 6 and the acid 9 led to compound 10 which could be
hydrogenated to obtain the alcohol 2. By subsequent oxidation of the alcohol 2 the acid 3 was formed
and finally converted to the compounds 4 and 5 by amide bond formation.
2.3. Biological Assays
Consecutively the synthesized compounds were tested for their inhibition activity against MMP-13
in in vitro assays. The values are averaged over triplicate determinations (Table 1).
Table 1. MMP-13 inhibitory data for compounds 1–5 and 11–18.
Structure Comp. % Activity 1 IC50 [µM] pIC50 clogP LE 2 LLE 3
1
ZHAWOC
928
25 ˘ 4 9.8 ˘ 3.4 5.01 3.94 0.25 1.07
11
ZHAWOC
4756
7.9 ˘ 0.4 0.586 ˘ 0.13 6.23 3.68 0.26 2.55
12
ZHAWOC
4757
7.6 ˘ 0.5 0.454 ˘ 0.20 6.34 4.12 0.26 2.22
2
ZHAWOC
5041
9.1 ˘ 0.9 0.822 ˘ 0.21 6.09 4.56 0.24 1.53
13
ZHAWOC
5042
33.0 ˘ 2.9 n.d.4 n.d.4 5.00 n.d.4 n.d.4
14
ZHAWOC
4767
15.4 ˘ 0.3 n.d.4 n.d.4 3.52 n.d.4 n.d.4
15
ZHAWOC
4768
4.6 ˘ 0.6 0.777 ˘ 0.05 6.11 3.95 0.24 2.16
3
ZHAWOC
5077
2.4 ˘ 0.1 0.134 ˘ 0.04 6.87 4.41 0.27 2.46
16
ZHAWOC
5078
2.6 ˘ 0.3 0.280 ˘ 0.04 6.55 4.85 0.25 1.70
17
ZHAWOC
5136
30.5 ˘ 0.8 n.d.4 n.d.4 2.70 n.d.4 n.d.4
18
ZHAWOC
5135
11.2 ˘ 0.3 0.896 ˘ 0.06 6.05 3.15 0.22 2.91
4
ZHAWOC
5079
13.8 ˘ 1.4 0.767 ˘ 0.08 6.12 3.59 0.21 2.53
5
ZHAWOC
5080
6.7 ˘ 0.5 0.328 ˘ 0.05 6.48 4.03 0.25 2.45
1 Remaining enzyme activity at 10 µM inhibitor concentration; 2 Ligand Efficiency (LE) was calculated as
1.4(´logIC50)/N; N equals the number of non-hydrogen atoms; 3 LLE = pIC50 - clogP; metric for the estimate
of drug likeness; 4 Not determined (n.d.) due to more than 15% remaining enzyme activity in single dose
inhibitory assays at 10 µM inhibitor concentration.
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The carboxylic acids 3 and 16 turned out to be the most potent inhibitors within this series (IC50:
134 nM (3), 280 nM (16)). The acyl sulfonamides 4 and 18 show some of the best lipophilic ligand
efficiencies (LLE: 2.53 (4), 2.91 (18)).
3. Discussion
We modified the allosteric inhibitor 1 of MMP-13 to increase its potency against the target enzyme
and to elevate the LLE of the initial inhibitor. Increased potency could be achieved by the addition of a
zinc binding fragment to the inhibitor. The carboxylic acid turned out to be the most potent option for
the molecular recognition of the catalytic zinc(II) ion. The new inhibitors combine allosteric interaction
with the recognition of the catalytic center to yield dual binding mode inhibitors. Compound 3
showed the highest affinity with an IC50 value of 134 nM. Increased LLE values were achieved by the
implementation of acyl sulfonamide fragments to 1 which lowered the clogP value of the respective
inhibitor. By comparing the acyl sulfonamide 18 with its carboxylic acid counterpart 15 one observes
that the LLE improves from 2.16 to 2.91, which is in the range of lead compounds, while the IC50
values are comparable. Therefore acyl sulfonamides are good bioisosteres for substituting carboxylic
acids as zinc binding functional groups if an increase of the LLE of MMP inhibitors is intended.
The results of the series with carboxylic acids as the zinc binding group clearly show that the
selection of excessively short linkers leads to a loss in potency. Also linkers with six heavy atoms
between the allosteric fragment and the zinc-recognizing acid cause diminished inhibition, leading to
an optimal linker length of five heavy atoms. These findings harmonize with our modeling results as
we observed better geometrical matches for linkers with medium lengths.
It should be mentioned that the critical observation of the generated docking poses with respect
to binding angles and torsions was absolutely mandatory for the successful outcome of this study.
The corresponding scoring values can only be compared for sets of molecules with comparable binding
modes, but even then it is safer to examine the poses visually instead of using the scoring values for
prioritizing compounds for synthesis.
4. Materials and Methods
4.1. General
All NMR spectra were recorded on a Bruker AVANCE III HD 500 One Bay spectrometer with
a magnetic field of 11.75 T. For 1H NMR spectra a frequency of 500 MHz resulted. Chemical
shifts are reported in ppm from tetramethylsilane as internal standard. Data are reported as
follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet,
quint. = quintet, br. = broad, m = multiplet), coupling constants (Hz). For 13C NMR spectra a frequency
of 125 MHz resulted. Chemical shifts are reported in ppm from tetramethylsilane as internal standard.
The multiplicities of the signals were determined by DEPT Measurements. High-resolution mass
spectrometry was performed on an Agilent Technologies 6530 Q-TOF. NMR spectra, HRMS spectra
and IC50 curves can be found in the supplementary materials.
4.2. Chemistry
All reagents and solvents used in the synthesis were purchased from Sigma Aldrich (Buchs,
Switzerland) or TCI (Zwijndrecht, Belgium) and used as received. Solvents were stored over molecular
sieves 4 Å.
Methyl 2-(3-{[5-(benzyloxy)pentyl]oxy}phenyl)acetate (8c; ZHAWOC4927): under an argon
atmosphere, methyl 2-(3-hydroxyphenyl)acetate (7) (2.5 g, 15.05 mmol) and caesium carbonate (9.81 g,
30.11 mmol) were suspended in dimethylformamide (100 mL), the mixture was stirred at ambient
temperature for 2 h. Benzyl-5-bromoamylether (4.26 g, 16.56 mmol) was added and it was stirred at
ambient temperature for further 12 h. Water (250 mL) and ethyl acetate (250 mL) was added and the
resulting phases separated. The organic phase was dried over sodium sulfate and concentrated in
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vacuum. Purification by chromatography on silica gel (Gradient: 0%–100% ethyl acetate in cyclohexane)
afforded the title compound 8c as a white solid (4.30 g, 83% yield): 1H-NMR (500 MHz, [D6]DMSO,
25 ˝C, TMS): δ = 7.35–7.31 (4H; m; C-Haromatic), 7.29–7.24 (1H; m; C-Haromatic), 7.20 (1H; t; J = 7.9 Hz;
C-Haromatic), 6.85–6.76 (3H; m; C-Haromatic), 4.50 (2H; s; CH2), 3.94 (2H; t; J = 6.5 Hz; CH2), 3.67 (3H; s;
CH3), 3.57 (2H; s; CH2), 3.49 (2H; t; J = 6.3 Hz; CH2), 1.82–1.75 (2H; m; CH2), 1.71–1.65 (2H; m; CH2),
1.59–1.51 (2H; m; CH2) ppm. 13C-NMR (125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 171.96, 159.28, 138.66,
135.37, 129.56, 128.41, 127.67, 127.55, 121.46, 115.54, 113.19, 72.97, 70.27, 67.77, 52.08, 41.27, 29.57, 29.15,
22.86 ppm. HRMS-TOF: m/z [M + H]+ calculated for C21H26O4: 343.1909, found: 343.1898.
In analogy to 8c the following derivatives were synthesized:
Methyl 2-(3-{[3-(benzyloxy)propyl]oxy}phenyl)acetate (8a; ZHAWOC4557): The title compound 8a
was obtained as a white solid in 80% yield: 1H-NMR (500 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 7.35–7.29
(4H; m; C-Haromatic), 7.29–7.24 (1H; m; C-Haromatic), 7.24–7.18 (1H; t; m; C-Haromatic), 6.86–6.76 (3H; m;
C-Haromatic), 4.51 (2H; s; CH2), 4.06 (2H; t; J = 6.3 Hz; CH2), 3.67 (3H; s; CH3), 3.65 (2H; t; J = 6.3 Hz;
CH2), 3.57 (2H; s; CH2), 2.07 (2H; quint; J = 6.19 Hz; CH2) ppm. 13C-NMR (125 MHz, [D6]DMSO, 25 ˝C,
TMS): δ = 171.93, 159.20, 138.47, 135.39, 129.56, 128.41, 127.65, 127.59, 121.56, 115.63, 113.21, 73.07, 66.87,
64.82, 52.06, 41.25, 29.80 ppm. MS: m/z [M + Na]+ 337.
Methyl 2-(3-{[4-(benzyloxy)butyl]oxy}phenyl)acetate (8b; ZHAWOC4558): The title compound 8b
was obtained as a white solid in 85% yield: 1H-NMR (500 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 7.35–7.30
(4H; m; C-Haromatic), 7.30–7.23 (1H; m; C-Haromatic), 7.22–7.16 (1H; t; m; C-Haromatic), 6.85–6.74 (3H; m;
C-Haromatic), 4.50 (2H; s; CH2), 3.95 (2H; t; J = 6.14 Hz; CH2), 3.66 (3H; s; CH3), 3.56 (2H; s; CH2), 3.52
(2H; t; J = 6.14 Hz; CH2), 1.93–1.72 (4H; m; CH2) ppm. 13C-NMR (125 MHz, [D6]DMSO, 25 ˝C, TMS):
δ = 171.93, 159.26, 138.63, 135.39, 129.56, 128.41, 127.67, 127.57, 121.49, 115.58, 113.20, 72.94, 69.98, 67.60,
52.04, 41.26, 26.42, 26.22 ppm. MS: m/z [M + Na]+ 351.
Methyl 2-(3-{[6-(benzyloxy)hexyl]oxy}phenyl)acetate (8d; ZHAWOC4928): The title compound 8d
was obtained as a white solid in 84% yield: 1H-NMR (500 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 7.35–7.31
(4H; m; C-Haromatic), 7.29–7.25 (1H; m; C-Haromatic), 7.21 (1H; t; J = 7.88 Hz; C-Haromatic), 6.85–6.77 (3H;
m; C-Haromatic), 4.50 (2H; s; CH2), 3.93 (2H; t; J = 6.5 Hz; CH2), 3.68 (3H; s; CH3), 3.58 (2H; s; CH2), 3.48
(2H; t; J = 6.5 Hz; CH2), 1.81–1.74 (2H; m; CH2), 1.68–1.62 (2H; m; CH2), 1.51–1.42 (4H; m; CH2) ppm.
13C-NMR (125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 171.97, 159.29, 138.69, 135.34, 129.54, 128.38, 127.66,
127.52, 121.43, 115.53, 113.19, 72.92, 70.35, 67.81, 52.07, 41.27, 29.74, 29.27, 26.03, 25.96 ppm. MS: m/z
[M + Na]+ 379.
2-(3-{[5-(benzyloxy)pentyl]oxy}phenyl)acetic acid (9c; ZHAWOC4929): The ester (8c) (4.30 g,
12.57 mmol) was dissolved in methanol (220 mL) and stirred at ambient temperature. Potassium
hydroxide 10% in water (220 mL) was added over 10 min. and the mixture was stirred for another
20 min. Methanol was removed in vacuum and the aqueous phase extracted with diethyl ether
(200 mL). The aqueous phase was acidified with concentrated hydrochloric acid and extracted with
diethyl ether (200 mL). The second organic phase was dried over sodium sulfate and concentrated
in vacuum to obtain the title compound 9c as a white solid (4.13 g, 100% yield) : 1H-NMR (500 MHz,
[D6]DMSO, 25 ˝C, TMS): δ = 7.35–7.31 (4H; m; C-Haromatic), 7.30–7.25 (1H; m; C-Haromatic), 7.21 (1H; t;
J = 7.9 Hz; C-Haromatic), 6.86–6.77 (3H; m; C-Haromatic), 4.51 (2H; s; CH2), 3.94 (2H; t; J = 6.6 Hz; CH2),
3.59 (2H; s; CH2), 3.50 (2H; t; J = 6.6 Hz; CH2), 1.82–1.75 (2H; m; CH2), 1.72–1.65 (2H; m; CH2), 1.58–1.50
(2H; m; CH2) ppm. 13C-NMR (125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 177.07, 159.27, 138.54, 134.73,
129.61, 128.40, 127.70, 127.57, 121.56, 115.66, 113.37, 72.94, 70.24, 67.77, 41.09, 29.50, 29.10, 22.80 ppm.
HRMS-TOF: m/z [M + H]+ calculated for C20H24O4: 329.1753, found: 329.1748.
In analogy to 9c the following derivatives were synthesized:
2-(3-{[3-(benzyloxy)propyl]oxy}phenyl)acetic acid (9a; ZHAWOC4559): The title compound 9a was
obtained as a white solid in 89% yield: 1H-NMR (500 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 8.46 (1H; br.
s.; COOH), 7.33–7.17 (6H; m; C-Haromatic), 6.87–6.77 (3H; m; C-Haromatic), 4.51 (2H; s; CH2), 4.05 (2H; t;
J = 6.2 Hz; CH2), 3.64 (2H; t; J = 6.2 Hz; CH2), 3.57 (2H; s; CH2), 2.06 (2H; quint; J = 6.2 Hz ; CH2) ppm.
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13C-NMR (125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 177.35, 159.20, 138.33, 134.79, 129.63, 128.43, 127.72,
127.65, 121.70, 115.82, 113.40, 73.06, 66.87, 64.84, 41.13, 29.73 ppm. MS: m/z [M ´ H]´ 299.
2-(3-{[4-(benzyloxy)butyl]oxy}phenyl)acetic acid (9b; ZHAWOC4560): The title compound 9b was
obtained as a white solid in quantitative yield: 1H-NMR (500 MHz, [D6]DMSO, 25 ˝C, TMS):
δ = 7.35–7.31 (4H; m; C-Haromatic), 7.30–7.25 (1H; m; C-Haromatic), 7.21 (1H; t; J = 7.8 Hz; C-Haromatic),
6.86–6.77 (3H; m; C-Haromatic), 4.51 (2H; s; CH2), 3.96 (2H; t; J = 6.4 Hz; CH2), 3.59 (2H; s; CH2), 3.54
(2H; t; J = 6.4 Hz; CH2), 1.90–1.83 (2H; m; CH2), 1.82–1.75 (2H; m; CH2) ppm. 13C-NMR (125 MHz,
[D6]DMSO, 25 ˝C, TMS): δ = 177.27, 159.24, 138.50, 134.69, 129.62, 128.41, 127.71, 127.59, 121.59, 115.68,
113.39, 72.92, 69.93, 67.59, 41.08, 26.35, 26.15 ppm. MS: m/z [M ´ H]´ 313.
2-(3-{[6-(benzyloxy)hexyl]oxy}phenyl)acetic acid (9d; ZHAWOC4930): The title compound 9d was
obtained as a white solid in 94% yield: 1H-NMR (500 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 7.35–7.31 (4H;
m; C-Haromatic), 7.29–7.24 (1H; m; C-Haromatic), 7.21 (1H; t; J = 7.8 Hz; C-Haromatic), 6.85–6.78 (3H; m;
C-Haromatic), 4.50 (2H; s; CH2), 3.92 (2H; t; J = 6.6 Hz; CH2), 3.58 (2H; s; CH2), 3.47 (2H; t; J = 6.6 Hz;
CH2), 1.80-1.73 (2H; m; CH2), 1.67–1.61 (2H; m; CH2), 1.50–1.38 (4H; m; CH2) ppm. 13C-NMR (125 MHz,
[D6]DMSO, 25 ˝C, TMS): δ = 177.17, 159.30, 138.55, 134.80, 129.61, 128.41, 127.73, 127.59, 121.57, 115.68,
113.40, 72.89, 70.34, 67.84, 41.15, 29.67, 29.24, 26.00, 25.94 ppm. MS: m/z [M ´ H]´ 341.
N-(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-2-(3-{[5-(benzyloxy)pentyl]oxy}phenyl)acetamide
(10c; ZHAWOC5606): The acid (9c) (4.10 g, 12.49 mmol) was stirred in an excess of thionylchloride at
55 ˝C for 1 h. After removal of excess thionylchloride in vacuum the acid chloride was dissolved in
tetrahydrofuran (10 mL) and added to a solution of 5-amino-2-benzylisoindoline-1,3-dione (6) (2.42 g,
9.60 mmol) in tetrahydrofuran (200 mL) under argon at ambient temperature. Diisopropylethylamine
(1.90 g, 14.70 mmol) was added and the mixture was stirred at ambient temperature for 2 h. After
removal of the tetrahydrofuran in vacuum, ethyl acetate (200 mL) and 10% citric acid (200 mL) were
added and the resulting phases were separated. The organic phase was washed with 10% sodium
bicarbonate (200 mL) and brine (200 mL), dried over sodium sulfate and concentrated in vacuum.
Purification by chromatography on silica gel (Gradient: 0%–100% ethyl acetate in cyclohexane)
afforded the title compound 10c as a yellow solid (3.56 g, 66% yield): 1H-NMR (500 MHz, [D6]DMSO,
25 ˝C, TMS): δ = 7.89 (1H; d; J = 2.1 Hz; C-Haromatic), 7.84 (1H; dd; J = 8.2 Hz, 2.1 Hz; C-Haromatic), 7.74
(1H; d; J = 8.2 Hz; C-Haromatic), 7.71 (1H; br. s; N-H), 7.43–7.39 (2H; m; C-Haromatic), 7.37–7.24 (9H; m;
C-Haromatic), 6.93–6.81 (3H; m; C-Haromatic), 4.82 (2H; s; CH2), 4.53 (2H; m; CH2), 3.98 (2H; t; J = 6.5 Hz;
CH2), 3.74 (2H; s; CH2), 3.53 (2H; t; J = 6.5 Hz; CH2), 1.87–1.77 (2H; m; CH2), 1.76–1.67 (2H; m; CH2),
1.63—-.53 (2H; m; CH2) ppm. 13C-NMR (125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 171.22, 169.33, 167.53,
159.83, 143.21, 136.35, 130.47, 128.66, 128.49, 128.38, 127.79, 127.65, 127.56, 124.45, 121.41, 115.83, 114.08,
113.76, 72.97, 70.23, 67.88, 44.88, 41.64, 29.52, 29.06, 22.84 ppm. HRMS-TOF: m/z [M + H]+ calculated
for C35H34N2O5: 563.2546, found: 563.2542.
In analogy to 10c the following derivatives were synthesized:
N-(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-2-(3-{[3-(benzyloxy)propyl]oxy}phenyl)acetamide
(10a; ZHAWOC4754): The title compound 10a was obtained as a yellow solid in 74% yield: 1H-NMR
(500 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 8.08 (1H; s; NH), 7.90 (1H; d; J = 1.8 Hz; C-Haromatic), 7.82 (1H;
dd; J = 8.2 Hz, 1.8 Hz; C-Haromatic), 7.68 (1H; d; J = 8.2 Hz; C-Haromatic), 7.39–7.19 (11H; m; C-Haromatic),
6.89–6.76 (3H; m; C-Haromatic), 4.78 (2H; s; CH2), 4.50 (2H; m; CH2), 4.05 (2H; t; J = 6.2 Hz; CH2),
3.67 (2H; s; CH2), 3.64 (2H; t; J = 6.2 Hz; CH2), 2.11–2.02 (2H; m; CH2) ppm. 13C-NMR (125 MHz,
[D6]DMSO, 25 ˝C, TMS): δ = 171.27, 169.55, 167.62, 167.57, 159.62, 143.46, 138.33, 136.36, 135.22, 133.51,
130.29, 128.66, 128.43, 128.39, 127.79, 127.61, 126.78, 124.42, 123.85, 121.47, 115.82, 114.14, 113.64, 73.04,
66.78, 64.92, 44.72, 41.62, 29.68 ppm. MS: m/z [M ´ H]´ 533; [M + Na]+ 557.
N-(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-2-(3-{[4-(benzyloxy)butyl]oxy}phenyl)acetamide
(10b; ZHAWOC4755): The title compound 10b was obtained as a yellow solid in 64% yield: 1H-NMR
(500 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 8.21 (1H; s; NH), 7.91 (1H; d; J = 1.9 Hz; C-Haromatic), 7.83 (1H;
dd; J = 8.2 Hz, 1.9 Hz; C-Haromatic), 7.68 (1H; d; J = 8.2 Hz; C-Haromatic), 7.40–7.19 (11H; m; C-Haromatic),
6.87–6.77 (3H; m; C-Haromatic), 4.78 (2H; s; CH2), 4.50 (2H; m; CH2), 3.94 (2H; t; J = 6.0 Hz; CH2),
Int. J. Mol. Sci. 2016, 17, 314 10 of 15
3.66 (2H; s; CH2), 3.53 (2H; t; J = 6.0 Hz; CH2), 1.92–1.71 (4H; m; CH2) ppm. 13C-NMR (125 MHz,
[D6]DMSO, 25 ˝C, TMS): δ = 169.63, 167.63, 167.58, 159.64, 143.53, 138.48, 136.37, 135.26, 133.49, 130.22,
128.66, 128.42, 128.38, 127.78, 127.64, 127.57, 126.74, 124.40, 123.86, 121.38, 115.79, 114.15, 113.51, 72.92,
69.93, 47.66, 44.68, 41.61, 26.34, 26.15 ppm. MS: m/z [M ´ H]´ 547; [M + Na]+ 571.
N-(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-2-(3-{[4-(benzyloxy)butyl]oxy}phenyl)acetamide
(10d): The title compound 10d was prepared from the acid 9d and used directly for further synthesis
without purification.
N-(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-2-{3-[(5-hydroxypentyl)oxy]phenyl}acetamide (2;
ZHAWOC5041): The benzyl ether (10c) (3.30 g, 5.87 mmol) was dissolved in ethanol (300 mL).
Palladium 10% on activated charcoal (0.70 g, 0.59 mmol) was added and a hydrogen atmosphere was
applied at 1 bar. After stirring at ambient temperature for 2 h the mixture was filtered over celite
and concentrated in vacuum. Purification by chromatography on silica gel (Gradient: 0%–100% ethyl
acetate in cyclohexane) afforded the title compound 2 as a white solid (2.30 g, 83% yield): 1H-NMR
(500 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 8.99 (1H; s; N-H), 7.98 (1H; d; J = 2 Hz; C-Haromatic), 7.83 (1H;
dd; J = 8.2 Hz, 2 Hz; C-Haromatic), 7.64 (1H; d; J = 8.2 Hz; C-Haromatic), 7.37–7.32 (2H; m; C-Haromatic),
7.28–7.12 (4H; m; C-Haromatic), 6.84–6.69 (3H; m; C-Haromatic), 4.76 (2H; s; CH2), 3.85 (2H; t; J = 6.3 Hz;
CH2), 3.64 (4H; br. s; 2 x CH2), 2.21 (1H; br. s; O-H), 1.77–1.69 (2H, m; CH2), 1.63–1.55 (2H; m; CH2),
1.53–1.44 (2H; m; CH2) ppm. 13C-NMR (125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 170.14, 167.68, 167.65,
159.38, 143.87, 136.33, 135.48, 133.34, 129.90, 128.61, 128.33, 127.74, 124.28, 123.93, 121.28, 112.72, 114.22,
113.08, 67.69, 62.48, 44.41, 41.54, 32.31, 28.94, 22.40 ppm. HRMS-TOF: m/z [M + H]+ calculated for
C28H28N2O5: 473.2076, found: 473.2076.
5-(3-{[(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)carbamoyl]methyl}phenoxy)pentanoic acid (3;
ZHAWOC5077): The alcohol (2) (2.20 g, 4.66 mmol), TEMPO (0.07 g, 0.352 mmol) and 0.67 M aqueous
sodium phosphate (22 mL) in acetonitrile (26.4 mL) were stirred and heated to 40 ˝C. NaClO2 (1.12 g,
9.90 mmol in 5 mL water) and 10% NaOCl (2.2 mL) were added in parallel dropwise and it was stirred
for 4 h. After cooling to ambient temperature water (20 mL) was added and the mixture was poured
in an ice could solution of Na2SO3 (1.8 g in 30 mL water). The aqueous phase was extracted with
diethylether (80 mL), acidified with 10% citric acid and again extracted with diethylether (2 ˆ 100 mL).
The organic phases were dried over sodium sulfate and concentrated in vacuum to obtain the title
compound 3 as a white solid (1.20 g, 53% yield): 1H-NMR (500 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 12.05
(1H; br. s; COOH), 10.77 (1H; s; N-H), 8.22 (1H; d; J = 1.6 Hz; C-Haromatic), 7.90 (1H; dd; J = 8.2 Hz,
1.6 Hz; C-Haromatic), 7.84 (1H; d; J = 8.2 Hz; C-Haromatic), 7.35–7.21 (6H; m; C-Haromatic), 6.93–6.80
(3H; m; C-Haromatic), 4.74 (2H; s; CH2), 3.96 (2H; t; J = 6.2 Hz; CH2), 3.69 (2H; s; CH2), 2.28 (2H; t;
J = 7.5 Hz; CH2), 1.76–1.69 (2H; m; CH2), 1.68–1.60 (2H; m; CH2) ppm. 13C-NMR (125 MHz, [D6]DMSO,
25 ˝C, TMS): δ = 174.82, 170.44, 167.93, 167.76, 159.08, 145.23, 137.21, 137.14, 129.85, 129.04, 127.85,
127.82, 125.78, 124.93, 123.86, 121.75, 116.00, 113.36, 113.04, 67.48, 43.86, 41.31, 33.79, 28.61, 21.70 ppm.
HRMS-TOF: m/z [M + H]+ calculated for C28H26N2O6: 487.1869, found: 487.1850.
5-(3-{[(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)carbamoyl]methyl}phenoxy)-N-methanesulfony
lpentanamide (4; ZHAWOC5079): The acid (3) (106 mg, 0.218 mmol) was dissolved in dichloromethane
(5 mL) and cooled to 0 ˝C. EDC¨HCl (63 mg, 0.327 mmol), methansulfonamide (23 mg, 0.240 mmol)
and DMAP (40 mg, 0.327 mmol) were added and stirred at 0 ˝C for further 20 min. After warming up
to ambient temperature it was stirred for another 12 h. The reaction was quenched by adding 10%
citric acid (5 mL). The precipitate was filtered off and dissolved in DMSO (1 mL). Purification by
reversed phase chromatography on silica gel C18 (Gradient: 0%–100% methanol in water) afforded the
title compound 4 as a white solid (50 mg, 41% yield): 1H-NMR (500 MHz, [D6]DMSO, 25 ˝C, TMS):
δ = 11.68 (1H; s; N-H), 10.76 (1H; s; N-H), 8.22 (1H; d: J = 1.9 Hz; C-Haromatic), 7.90 (1H; dd; J = 8.5 Hz,
1.9 Hz; C-Haromatic), 7.85 (1H; d; J = 8.5 Hz; C-Haromatic), 7.35–7.21 (6H; m; C-Haromatic), 6.94–6.81 (3H;
m; C-Haromatic), 4.74 (2H; s; CH2), 3.96 (2H; t; J = 5.7 Hz; CH2), 3.69 (2H; s; CH2), 3.22 (3H; s ; CH3), 2.35
(2H; t; J = 7.2 Hz; CH2), 1.76–1.60 (4H; m; 2 ˆ CH2) ppm. 13C-NMR (125 MHz, [D6]DMSO, 25 ˝C,
TMS): δ = 172.94, 170.43, 167.93, 167.76, 159.05, 145.22, 137.21, 137.15, 133.55, 129.85, 129.04, 127.86,
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127.83, 125.79, 124.94, 123.85, 121.80, 115.99, 113.35, 113.06, 67.37, 43.84, 41.45, 41.32, 35.47, 28.42,
21.29 ppm. HRMS-TOF: m/z [M + H]+ calculated for C29H29N3O7S: 564.1804, found: 564.1808.
5-(3-{[(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)carbamoyl]methyl}phenoxy)-N-methylpentanamide (5;
ZHAWOC5080): The acid (3) (100 mg, 0.206 mmol) was dissolved in tetrahydrofuran (3 mL) and
diisopropylethylamine (138 mg, 1.070 mmol), HATU (215 mg, 0.565 mmol) such as methylamine 2 M
in THF (0.206 mL, 0.412 mmol) were added. The mixture was stirred at ambient temperature for 18 h
before it was concentrated in vacuum and purified by chromatography on silica gel (Gradient: 0%–100%
ethyl acetate in Cyclohexane) to obtain the title compound 5 as a white solid (40 mg, 39% yield): 1H-NMR
(500 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 10.76 (1H; s; N-H), 8.21 (1H; d; J = 1.9 Hz; C-Haromatic), 7.90 (1H;
dd; J = 8.2 Hz, 1.9 Hz; C-Haromatic), 7.84 (1H; d; J = 8.2 Hz; C-Haromatic), 7.71 (1H; br. q; J = 4.5 Hz; N-H),
7.35–7.20 (6H; m; C-Haromatic), 6.92–6.79 (3H; m; C-Haromatic), 4.74 (2H; s; CH2), 3.94 (2H; t; J = 6 Hz; CH2),
3.68 (2H; s; CH2), 2.55 (3H; d; J = 4.5 Hz; CH3), 2.11 (2H; t; J = 7.3 Hz; CH2), 1.72–1.58 (4H; m; 2 ˆ CH2)
ppm. 13C-NMR (125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 172.71, 170.44, 167.93 167.76, 159.09, 145.23,
137.21, 137.14, 129.84, 129.04, 127.86, 127.83, 125.79, 124.93, 123.85, 121.74, 115.98, 113.36, 113.05, 67.46, 43.85,
41.32, 35.38, 28.78, 25.87, 22.36 ppm. HRMS-TOF: m/z [M + H]+ calculated for C29H29N3O5: 500.2185,
found: 500.2181.
The following alcohols were synthesized according to compound (2):
N-(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-2-[3-(3-hydroxypropoxy)phenyl]acetamide (11;
ZHAWOC4756): The title compound was isolated as a white solid in 57% yield: 1H-NMR (500 MHz,
[D6]DMSO, 25 ˝C, TMS): δ = 8.95 (1H; s; N-H), 7.95 (1H; d; J = 1.7 Hz; C-Haromatic), 7.77 (1H; dd;
J = 8.2 Hz, 1.7 Hz; C-Haromatic), 7.60 (1H; d; J = 8.2 Hz; C-Haromatic), 7.38–7.05 (6H; m; C-Haromatic),
6.82–6.64 (3H; m; C-Haromatic), 4.74 (2H; s; CH2), 3.97 (2H; t; J = 6 Hz; CH2), 3.77 (2H; t; J = 5.9 Hz; CH2),
3.58 (2H; s; CH2), 2.95 (1H; br. s; O-H), 1.94 (2H; quint.; J = 5.9 Hz; CH2) ppm. 13C-NMR (125 MHz,
[D6]DMSO, 25 ˝C, TMS): δ = 170.31, 167.82, 167.73, 159.19, 143.74, 136.27, 135.46, 133.32, 130.02, 128.69,
128.34, 127.84, 126.55, 124.36, 124.08, 121.57, 115.70, 114.32, 113.20, 65.09, 59.68, 44.37, 41.62, 31.97 ppm.
HRMS-TOF: m/z [M + H]+ calculated for C26H24N2O5: 445.1763, found: 445.1776.
N-(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-2-[3-(4-hydroxybutoxy)phenyl]acetamide (12;
ZHAWOC4757): The title compound was isolated as a white solid in 48% yield: 1H-NMR (500 MHz,
[D6]DMSO, 25 ˝C, TMS): δ = 8.93 (1H; s; N-H), 7.96 (1H; d; J = 1.75 Hz; C-Haromatic), 7.80 (1H; dd;
J = 8.2 Hz, 1.75 Hz; C-Haromatic), 7.62 (1H; d; J = 8.2 Hz; C-Haromatic), 7.38–7.10 (6H; m; C-Haromatic),
6.85–6.66 (3H; m; C-Haromatic), 4.74 (2H; s; CH2), 3.87 (2H; t; J = 6 Hz; CH2), 3.66 (2H; t; J = 6.3 Hz;
CH2), 3.61 (2H; s; CH2), 2.84 (1H; br. s; O-H), 1.85–1.73 (2H; m; CH2), 1.73–1.60 (2H; m; CH2) ppm.
13C-NMR (125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 170.26, 167.82, 167.72, 159.27, 143.78, 136.28, 135.47,
133.35, 130.04, 128.68, 128.34, 127.83, 126.55, 124.38, 124.06, 121.50, 115.83, 114.32, 113.18, 67.70, 62.35,
44.42, 41.61, 29.30, 25.76 ppm. HRMS-TOF: m/z [M + H]+ calculated for C27H26N2O5: 459.1920,
found: 459.1922.
N-(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-2-{3-[(6-hydroxyhexyl)oxy]phenyl}acetamide (13;
ZHAWOC5042): The title compound was isolated as a white solid in 77% yield: 1H-NMR (500 MHz,
[D6]DMSO, 25 ˝C, TMS): δ = 8.74 (1H; s; N-H), 7.94 (1H; d; J = 1.8 Hz; C-Haromatic), 7.82 (1H; dd;
J = 8.2 Hz, 1.8 Hz; C-Haromatic), 7.65 (1H; d; J = 8.2 Hz; C-Haromatic), 7.38–7.32 (2H; m; C-Haromatic),
7.29–7.15 (4H; m; C-Haromatic), 6.85–6.72 (3H; m; C-Haromatic), 4.76 (2H; s; CH2), 3.86 (2H; t; J = 6.4 Hz;
CH2), 3.64 (2H; s; CH2), 3.63 (2H; t; J = 6.5 Hz; CH2), 2.41 (1H; br. s; O-H), 1.76–1.67 (2H; m; ; CH2),
1.60–1.53 (2H; m; ; CH2), 1.47–1.33 (4H; m; ; CH2) ppm. 13C-NMR (125 MHz, [D6]DMSO, 25 ˝C,
TMS): δ = 170.08, 167.74, 167.67, 159.51, 143.74, 136.30, 135.38, 133.38, 130.06, 128.67, 128.36, 127.80,
126.58, 124.38, 121.33, 115.76, 114.25, 113.30, 67.78, 62.71, 44.53, 41.61, 32.58, 29.13, 25.82, 25.53 ppm.
HRMS-TOF: m/z [M + H]+ calculated for C29H30N2O5: 487.2233, found: 487.2211.
The following acids were synthesized according to compound (3):
3-(3-{[(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)carbamoyl]methyl}phenoxy)propanoic acid (14;
ZHAWOC4767): The title compound was isolated as a white solid in 51% yield: 1H-NMR (500 MHz,
[D6]DMSO, 25 ˝C, TMS): δ = 12.35 (1H; br. s; COOH), 10.76 (1H; s; N-H), 8.21 (1H; d; J = 1.7 Hz;
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C-Haromatic), 7.90 (1H; dd; J = 8.2 Hz, 1.7 Hz; C-Haromatic), 7.84 (1H; d; J = 8.2 Hz; C-Haromatic), 7.36–7.19
(6H; m; C-Haromatic), 6.96–6.78 (3H; m; C-Haromatic), 4.74 (2H; s; CH2), 4.15 (2H; t; J = 6 Hz; CH2), 3.69
(2H; s; CH2), 2.69 (2H; t; J = 6 Hz; CH2) ppm. 13C-NMR (125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 172.71,
170.42, 167.93, 167.76, 158.80, 145.23, 137.21, 133.55, 129.89, 129.04, 127.83, 125.79, 124.93, 123.86,
122.00, 115.91, 113.37, 113.10, 63.95, 43.83, 41.31, 34.56 ppm. HRMS-TOF: m/z [M + H]+ calculated for
C26H22N2O6: 459.1556, found: 459.1557.
4-(3-{[(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)carbamoyl]methyl}phenoxy)butanoic acid (15;
ZHAWOC4768): The title compound was isolated as a white solid in 84% yield: 1H-NMR (500 MHz,
[D6]DMSO, 25 ˝C, TMS): δ = 12.12 (1H; br. s; COOH), 10.76 (1H; s; N-H), 8.21 (1H; d; J = 1.7 Hz;
C-Haromatic), 7.90 (1H; dd; J = 8.2 Hz, 1.7 Hz; C-Haromatic), 7.84 (1H; d; J = 8.2 Hz; C-Haromatic), 7.37–7.18
(6H; m; C-Haromatic), 6.95–6.78 (3H; m; C-Haromatic), 4.74 (2H; s; CH2), 3.97 (2H; t; J = 6.4 Hz; CH2),
3.68 (2H; s; CH2), 2.38 (2H; t; J = 7.4 Hz; CH2), 1.93 (2H; quint.; J = 6.7 Hz; CH2) ppm. 13C-NMR
(125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 174.62, 170.44, 167.93, 167.76, 158.97, 145.24, 137.21, 137.17,
129.86, 129.04, 127.85, 127.82, 124.92, 123.86, 121.83, 115.95, 113.37, 113.11, 66.97, 43.84, 41.31, 30.72,
24.80 ppm. HRMS-TOF: m/z [M + H]+ calculated for C27H24N2O6: 473.1712, found: 473.1709.
6-(3-{[(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)carbamoyl]methyl}phenoxy)hexanoic acid (16;
ZHAWOC5078): The title compound was isolated as a white solid in 87% yield: 1H-NMR (500 MHz,
[D6]DMSO, 25 ˝C, TMS): δ = 11.82 (1H; br. s; COOH), 10.78 (1H; s; N-H), 8.21 (1H; d; J = 1.8 Hz;
C-Haromatic), 7.90 (1H; dd; J = 8.2 Hz, 1.8 Hz; C-Haromatic), 7.83 (1H; d; J = 8.2 Hz; C-Haromatic), 7.35–7.19
(6H; m; C-Haromatic), 6.93–6.78 (3H; m; C-Haromatic), 4.73 (2H; s; CH2), 3.93 (2H; t; J = 6.3 Hz; CH2), 3.68
(2H; s; CH2), 2.22 (2H; t; J = 7.3 Hz; CH2), 1.73–1.66 (2H; m; CH2), 1.59–1.51 (2H; m; CH2), 1.45–1.37
(2H; m; CH2) ppm. 13C-NMR (125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 174.94, 170.45, 167.92, 167.75,
159.11, 145.24, 137.20, 137.14, 129.84, 129.04, 127.85, 127.82, 125.77, 124.91, 123.85, 121.72, 115.96, 113.36,
113.05, 67.67, 43.86, 41.31, 34.19, 28.93, 25.65, 24.79 ppm. HRMS-TOF: m/z [M + H]+ calculated for
C29H28N2O6: 501.2025, found: 501.2022.
The following acyl sulfonamides were synthesized according to compound (4):
3-(3-{[(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)carbamoyl]methyl}phenoxy)-N-methanesulfony
lpropanamide (17; ZHAWOC5136): The title compound was isolated as a white solid in 19% yield:
1H-NMR (500 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 11.86 (1H; s; N-H), 10.77 (1H; s; N-H), 8.21 (1H;
d: J = 1.9 Hz; C-Haromatic), 7.89 (1H; dd; J = 8.2 Hz, 1.9 Hz; C-Haromatic), 7.84 (1H; d; J = 8.2 Hz;
C-Haromatic), 7.35–7.21 (6H; m; C-Haromatic), 6.94–6.81 (3H; m; C-Haromatic), 4.74 (2H; s; CH2), 4.18 (2H;
t; J = 6 Hz; CH2), 3.69 (2H; s; CH2), 3.22 (3H; s ; CH3), 2.75 (2H; t; J = 6 Hz; CH2) ppm. 13C-NMR
(125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 170.90, 170.41, 167.93, 167.76, 158.72, 145.22, 137.21, 133.55,
129.90, 129.04, 127.86, 127.82, 125.80, 124.94, 123.86, 122.10, 115.99, 113.16, 63.33, 43.82, 41.46, 41.32,
36.15 ppm. HRMS-TOF: m/z [M + H]+ calculated for C27H25N3O7S: 536.1491, found: 536.1483.
4-(3-{[(2-benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)carbamoyl]methyl}phenoxy)-N-methanesulfony
lbutanamide (18; ZHAWOC5135): The title compound was isolated as a white solid in 26% yield:
1H-NMR (500 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 11.71 (1H; s; N-H), 10.77 (1H; s; N-H), 8.21 (1H;
d: J = 1.8 Hz; C-Haromatic), 7.89 (1H; dd; J = 8.2 Hz, 1.8 Hz; C-Haromatic), 7.84 (1H; d; J = 8.2 Hz;
C-Haromatic), 7.35–7.21 (6H; m; C-Haromatic), 6.93–6.80 (3H; m; C-Haromatic), 4.74 (2H; s; CH2), 3.96 (2H; t;
J = 6.2 Hz; CH2), 3.68 (2H; s; CH2), 3.21 (3H; s ; CH3), 2.44 (2H; t; J = 7.4 Hz; CH2), 1.95 (2H; quint.;
J = 6.7 Hz; CH2) ppm. 13C-NMR (125 MHz, [D6]DMSO, 25 ˝C, TMS): δ = 172.77, 170.42, 167.93, 167.76,
158.92, 145.22, 137.21, 137.18, 133.55, 129.87, 129.04, 127.86, 127.83, 125.80, 124.94, 123.86, 121.90, 115.93,
113.36, 113.13, 66.89, 43.83, 41.46, 41.32, 32.55, 24.15 ppm. HRMS-TOF: m/z [M + H]+ calculated for
C28H27N3O7S: 550.1648, found: 550.1640.
4.3. In Silico Studies
Molecular modeling experiments were performed using the Molecular Operating Environment
MOE 2013.08 from Chemical Computing Group (www.chemcomp.com). Co-crystal structures of
MMP-13 are available from the Protein Data Bank (www.rcsb.org). For the actual work PDB code
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2OW9 was selected for the computational studies. In MOE the duplicates were eliminated using the
sequence editor and the pocket was prepared for the docking studies via the Protonate 3D method
applying the default values for temperature 300 K, pH 7 and salt 0.1. The ligands to be docked to the
protein were imported from structural data files (SD files) to receive a MOE compatible molecular
database. As the SD files did not contain 3D coordinates, they were generated directly using MOE
rebuild3D with a root mean square deviation (RMSD) gradient of 0.1. For docking experiments the
Amber10:EHT force field [32,33] was used. The pharmacophore placement was applied with the
pharmacophore set of three hydrogen bond acceptors (Acc1) used in the query. The docked poses were
subsequently analyzed with respect to their scores and interactions with the catalytic zinc ion.
4.4. In Vitro Assays
IC50 values were determined at Reaction Biology Corporation, Malvern, PA, USA in triplicates
using 10 concentrations starting at 10 µM with 3 fold dilution. The substrate used for the determinations
was the (5-FAM/QXLTM) FRET peptide. The buffer consisted of 50 mM HEPES at pH 7.5 with 10 mM
CaCl2 and 0.01% Brij-35. 0.1 mg/mL BSA was added before use. As a control inhibitor GM6001
was used.
5. Conclusions
In conclusion, we could employ molecular recognition for evolving an allosteric inhibitor through
the addition of properly arranged weak zinc binding fragments to obtain an inhibitor with dual
binding mode. In addition, the lipophilic ligand efficiency could be improved to lead-like level.
For the definite confirmation of the binding mode, a co-crystal structure of the complex is required.
This work is currently ongoing in our lab.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/17/
3/314/s1.
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